NASDAQ:NURO - Neurometrix Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.00 +0.05 (+5.26 %)
(As of 02/20/2019 08:00 AM ET)
Previous Close$0.95
Today's Range$0.95 - $1.00
52-Week Range$0.60 - $1.89
Volume38,400 shs
Average Volume100,890 shs
Market Capitalization$7.68 million
P/E Ratio13.57
Dividend YieldN/A
Beta0.51
NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; ADVANCE system, a platform for the performance of traditional nerve conduction studies; and SENSUS, a pain therapy device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain. The company offers its products to consumers, retail merchandisers, direct response TV promoters, health care professionals, managed care organizations, endocrinologists, podiatrists, physicians, neurologists, and physical medicine and rehabilitation centers, as well as primary care, internal medicine, orthopedic, hand, and neurosurgeons. It operates in the United States, Europe, Japan, China, the Middle East, and Mexico. The company has a strategic collaboration with GlaxoSmithKline. NeuroMetrix, Inc. was founded in 1996 and is headquartered in Waltham, Massachusetts.

Receive NURO News and Ratings via Email

Sign-up to receive the latest news and ratings for NURO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NURO
CUSIPN/A
Phone781-890-9989

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.09 million
Cash Flow$0.0252 per share
Book Value$0.79 per share

Profitability

Net Income$20,000.00

Miscellaneous

Employees42
Market Cap$7.68 million
OptionableNot Optionable

Neurometrix (NASDAQ:NURO) Frequently Asked Questions

What is Neurometrix's stock symbol?

Neurometrix trades on the NASDAQ under the ticker symbol "NURO."

When did Neurometrix's stock split? How did Neurometrix's stock split work?

Neurometrix shares reverse split on Friday, May 12th 2017. The 1-8 reverse split was announced on Thursday, May 11th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 11th 2017. An investor that had 100 shares of Neurometrix stock prior to the reverse split would have 13 shares after the split.

How were Neurometrix's earnings last quarter?

Neurometrix Inc (NASDAQ:NURO) announced its quarterly earnings data on Wednesday, October, 17th. The medical device company reported $0.15 EPS for the quarter, beating the Zacks' consensus estimate of ($0.19) by $0.34. The medical device company had revenue of $3.67 million for the quarter. Neurometrix had a return on equity of 0.31% and a net margin of 0.14%. View Neurometrix's Earnings History.

When is Neurometrix's next earnings date?

Neurometrix is scheduled to release their next quarterly earnings announcement on Friday, April 19th 2019. View Earnings Estimates for Neurometrix.

What is the consensus analysts' recommendation for Neurometrix?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurometrix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurometrix.

Has Neurometrix been receiving favorable news coverage?

Media stories about NURO stock have trended somewhat positive on Wednesday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Neurometrix earned a news impact score of 1.7 on InfoTrie's scale. They also assigned headlines about the medical device company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future.

Who are some of Neurometrix's key competitors?

Who are Neurometrix's key executives?

Neurometrix's management team includes the folowing people:
  • Dr. Shai N. Gozani, Founder, Chairman, CEO, Pres & Sec. (Age 54)
  • Mr. Thomas T. Higgins, Sr. VP, CFO & Treasurer (Age 67)
  • Mr. Francis X. McGillin, Sr. VP & Chief Commercial Officer (Age 58)
  • Mr. Richard J. Thomas, Pres
  • Mr. Michael J. MacDonald, Sr. VP & GM of Diagnostics

How do I buy shares of Neurometrix?

Shares of NURO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neurometrix's stock price today?

One share of NURO stock can currently be purchased for approximately $1.00.

How big of a company is Neurometrix?

Neurometrix has a market capitalization of $7.68 million and generates $16.09 million in revenue each year. Neurometrix employs 42 workers across the globe.

What is Neurometrix's official website?

The official website for Neurometrix is http://www.neurometrix.com.

How can I contact Neurometrix?

Neurometrix's mailing address is 1000 WINTER STREET, WALTHAM MA, 02451. The medical device company can be reached via phone at 781-890-9989 or via email at [email protected]


MarketBeat Community Rating for Neurometrix (NASDAQ NURO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  191 (Vote Outperform)
Underperform Votes:  139 (Vote Underperform)
Total Votes:  330
MarketBeat's community ratings are surveys of what our community members think about Neurometrix and other stocks. Vote "Outperform" if you believe NURO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NURO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel